© 2021 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
April 29, 2021
Toni Choueiri, MD, closes with promising new studies that will impact metastatic clear-cell renal cell carcinoma therapeutics in the years to come.
Both nivolumab + ipilimumab and lenvatinib + pembrolizumab TKI/IO combinations are discussed, with patient selection and appropriate use being the focus.
Dosing strategies to achieve strong efficacy and ameliorate adverse events with the combination of lenvatinib + pembrolizumab in metastatic clear-cell renal cell carcinoma.
April 20, 2021
Hutson and Choueiri compare the safety profiles of lenvatinib + pembrolizumab against other TKI/IO combinations for patients with metastatic clear-cell renal cell carcinoma.
Thomas Hutson, DO, PharmD, and Toni Choueiri, MD, talk about the phase 3 CLEAR trial at length, including each of the 3 arms of the trial and key data.
Hutson and Choueiri elaborate on the FDA-approved TKI + ICI combinations and their data from the following trials: KEYNOTE-146, JAVELIN Renal 101, and CheckMate-9ER.